A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
Background: Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due...
Hlavní autoři: | , , , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
SAGE Publishing
2023-08-01
|
Edice: | Therapeutic Advances in Medical Oncology |
On-line přístup: | https://doi.org/10.1177/17588359231181500 |